Effects of losartan in patients with NAFLD: A meta-analysis of randomized controlled trial

• Published in: Open life sciences Vol. 18; no. 1; p. 20220583
• Main Authors: Meng, Chang, Song, Zejun, Zhang, Lingnan, Geng, Yu, Sun, Jing, Miao, Guobin, Liu, Peng
• Format: Journal Article
• Language: English
• Published: Poland De Gruyter 21-03-2023
• Subjects: blood lipids; liver function; losartan; non-alcoholic fatty liver disease; Review; non-alcoholic fatty liver disease; losartan; blood lipids; liver function
• ISSN: 2391-5412; 2391-5412
• DOI: 10.1515/biol-2022-0583

Losartan has become a hot spot in the treatment of non-alcoholic fatty liver disease (NAFLD) among angiotensin receptor blocker drugs. We sought to conduct a systematic examination and meta-analysis to examine the effects of losartan on patients with NAFLD. We searched for potentially randomized controlled trials in PubMed, Embase, China National Knowledge Infrastructure, Wanfang, and the Cochrane database up to October 09, 2022. We used the Cochrane risk of bias tool to evaluate the study quality. Analysis of subgroups, sensitivity analysis, and publishing bias were explored. The quality of the included studies was moderate to high. Six trials involving 408 patients were included. The meta-analysis demonstrated that aspartate transaminase was significantly affected by losartan therapy (mean difference [MD] = −5.34, 95% confidence interval [CI] [−6.54, −4.13],
= 8.70,
< 0.01). The meta-analysis subgroup showed that losartan 50 mg once daily could lower the level of alanine aminotransferase (MD = −18.92, 95% CI [−21.18, −16.66],
= 16.41,
< 0.01). There was no statistically significant difference in serum total cholesterol, triglyceride, low-density lipoprotein, and high-density lipoprotein.